Amryt Pharma Share Discussion Threads

[papillon] 14/4/2017 22:18

runwaypaul14 Apr '17 - 16:12 - 1038 of 1038 0 0 (Filtered)

>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>

Anyway there are far more important happenings in the world at the moment than the AMYT share price and nasty pumpers and dumpers with multiple posting names like runwaypaul.

[runwaypaul] 14/4/2017 16:12

always has to get the last word in...so worried about the £400 profit slipping away

pmsl

[papillon] 14/4/2017 14:34

runwaypaul13 Apr '17 - 22:57 - 1034 of 1034 0 0 (Filtered)

It's likely that we will see a pull back on profit taking next week after this weeks 25%+ rise in the share price bwtfdik? I don't think it's worthwhile a small holder like me contemplating selling in the hope of buying back in cheaper; dealing expenses etc. Also I'd be taking a risk I could get back in cheaper! Happy to hold as I believe that the AMYT share price will be significantly higher than the current 27p by the end of 2017. As always fingers crossed!

My small holding in AMYT and an even smaller holding in GCL are the only shares I hold. Was thinking of buying some PVR.

[runwaypaul] 13/4/2017 22:57

u bank it?

bankit

[papillon] 13/4/2017 21:59

Interesting post on the lse bb: SOM is owned by AMYT

equitrder
Posts: 720
Off Topic
Opinion: No Opinion
Price: 27.00
Alan Harris Som 4% stakeholder Today 21:17 Alan Harris, the founder of Som,
was involved in developing a therapy
for these surgery-resistant patients
with Acromegaly when he was at
Novartis. The product is called
Octreotide, which is now a 1.65
billion dollar product. So, within the
cohort of patients who have failed
surgical treatment, most of them are
on Octreotide or another product
called Ianreotide. These are both
somatostatin analogues, and will
work fully in roughly 30% of patients
who try them. The remaining 70%
need an alternate treatment.
Novartis realised this, as did Pfizer,
and developed other products.
Novartis brought a product called
Pasireotide, and Pfizer brought
a product called Pegvisomant.
Pegvisomant is a growth hormone
receptor antibody. It acts as an
antagonist, blocking the receptor
and reducing the action of growth
hormone. There are two problems
with growth hormone receptor
antagonists – the first is that it has
no effect on the tumour size, only
on the action of growth hormone.
Secondly, it has a tendency to
elevate liver enzymes.
Pasireotide, however, is a
somatostatin analogue, so it does
have an effect on the tumour. It
binds to somatostatin receptors two
and five. Octreotide only binds to
receptor 2. Pasireotide is clinically
effective, but it can cause diabetes as
a side effect.
Alan set up Som Pharmaceuticals
to develop a new somatostatin
analogue. He wanted to find a
product as effective as pasireotide,
that did not cause diabetes.

[pottermagic2310] 13/4/2017 15:25

Oo-er !!

Price (GBX) 27.00 Var % (+/-) +2.86% (Up +0.75)
High 27.50 Low 24.25
Volume 471,689 Last close 26.25 on 12-Apr-2017
Bid 26.00 Offer 28.00

[runwaypaul] 13/4/2017 10:55

hot stockrocket chancers

pmsl

[bigwavedave] 13/4/2017 10:52

They now say "Hold".

[papillon] 13/4/2017 10:48

runwaypaul13 Apr '17 - 09:36 - 1027 of 1027 0 0 (Filtered). Pumper and dumper!

It looks like Zak Mir (and Hot Stock Rockets) were right (well tipsters do get it right, now and again! LOL) and 27p was the likely short term target.

[runwaypaul] 13/4/2017 09:36

no profit till its banked....


ssssSSPIKE!

[alphabravo321] 12/4/2017 21:55

A great few days...as WB said, "the stock market is a tool for transferring wealth from impatient people to patient people"

[papillon] 12/4/2017 17:18

I hope Pottermagic didn't take stevio's BLATANT attempts at deramping literally and sell his AMYT shares before this weeks rise!! The "elephant in the room" you mentioned, Pottermagic, turned out to be STEVIO and his blatant deramping!! If you did believe his devious attempt to prove that AMYT would imminently run out of cash and thus conveniently ignore the so far untouched Euro20m facility more fool you.

Unfortunately the advfn and lse bb's are choke full of devious pumpers and dumpers like stevio, mr hangman & runwaypaul. I would like to see people forced to post under their real names.

[papillon] 12/4/2017 17:01

papillon
12 Apr '17 - 12:59 - 1008 of 1023    0   0   Edit
Well the chartist Zak Mir (definitely NOT infallible!! LOL) gave a short term 27p share price target recently. That 27p share price target was reiterated by HotStockRockets (again NOT an infallible tipster!! LOL). Is that 27p on the cards shortly?

mr hangman
12 Apr '17 - 13:00 - 1009 of 1023    0   0
DOUBT IT

>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>

LOL. mr hangman got his big head caught in his noose! LOL.

[papillon] 12/4/2017 16:43

Still not a lot of posts today on the advfn & lse bb's. AMYT still under the radar of most investors?

[888icb] 12/4/2017 15:22

Market Cap now £53 million

[bigwavedave] 12/4/2017 15:14

I wish I knew papillon! But agree that it's more than just director buying (although that helps). Like I said the other day - when it was FAST at 3p (24p) it had no income and no future. When it became AMYT it had no income and an uncertain future. Looks much better now business-wise, so maybe people waking up to its true value like you said. Will likely see some trades on the back of this rise though...but fingers crossed and all that.

[papillon] 12/4/2017 14:55

I think you could be right there, bwd! I wonder what has prompted the sudden enthusiasm for AMYT shares? I can't believe it's solely due to Monday's after hours RNS of a £21k share purchase by a non exec member of the BoD. Could it be the buying is due to clients of the two brokers who recently issued bullish notes? Or due to investors waking up to the fact that AMYT is apparently being undervalued by the market? Hopefully we might see an RNS soon that will shed more light on the reason?

[bigwavedave] 12/4/2017 14:45

Er, never mind. I'll assume it's strong ;-)

[bigwavedave] 12/4/2017 14:02

Anyone with L2 insight?

[888icb] 12/4/2017 13:55

Another small push and the market cap will be £50 million.